Russia begins mass trials of second coronavirus vaccine
Russia plans to begin mass trials of its second coronavirus vaccine, EpiVacCorona, on people aged over 18 on Monday, the RIA news agency has cited the consumer health watchdog Rospotrebnadzor as saying.
EpiVacCorona, which is being developed by Siberia's Vector Institute, was authorized this month to carry out trials on 150 volunteers over 60 and 3,000 volunteers over 18, the watchdog has said.
The trials will be conducted in Moscow and several other cities, including Kazan and Kaliningrad, the TASS news agency cited it as saying.
Coronavirus cases have surged in Russia since September, but authorities have resisted imposing a touch lockdown and have said that targeted measures are enough to cope with the crisis.
Russia said earlier this month that its other Sputnik V vaccine was 92% effective at protecting people from COVID-19 according to interim results.
Authorities confirmed 26,338 new coronavirus cases on Monday, including 6,511 in Moscow and 3,691 in St Petersburg, taking the national total to 2,295,654 since the pandemic began.
They also reported 368 deaths in the last 24 hours, pushing the official death toll to 39,895.
(Source: Reuters)
Russia downs over 40 Ukrainian drones as Putin vows 'destruction' on Kiev
Ukraine to cede territory despite US support: Report
Russia arrests suspect 'recruited by Ukraine' over killing of top general
VIDEO | Iran-Syria: For Resistance
Qassam Brigades claims killing 3 Israeli troops in northern Gaza
More alive than ever: Sayyed Hassan Nasrallah's legacy grows stronger in martyrdom
Occupation of Syria’s highest peak Mount Hermon part of ‘Greater Israel’ project
Iran: Syrian people will decide their future without foreign interference
IRGC says Iran’s power exceeds borders, warns enemies to adjust themselves
Dozens detained, several wounded in Israeli raids in West Bank
‘Ethnic cleansing’: Hamas blasts Israeli attacks on Gaza hospital amid intl. silence
PressTV NEWSLETTER
now
This makes it easy to access the Press TV website
